Occurrence of Cystic Fibrosis Transmembrane Conductance Regulator Gene Mutations in Patients with Allergic Bronchopulmonary Aspergillosis Complicating Asthma.
ABPA
Aspergillus
CF
Mutation
NGS
Polymorphism
Journal
Mycopathologia
ISSN: 1573-0832
Titre abrégé: Mycopathologia
Pays: Netherlands
ID NLM: 7505689
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
10
02
2022
accepted:
31
03
2022
pubmed:
18
4
2022
medline:
25
5
2022
entrez:
17
4
2022
Statut:
ppublish
Résumé
Whether cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations contribute to the high prevalence of allergic bronchopulmonary aspergillosis (ABPA) in India remains unknown. We aimed to evaluate the occurrence of CFTR mutations in subjects with ABPA complicating asthma. We sequenced the CFTR gene using genomic DNA from blood on the Illumina NextSeq500 platform. Before undertaking zygosity analysis by genome analysis toolkit, the known or novel single nucleotide polymorphisms (SNPs) and indels were called. For rigorous analysis, we included only high-quality SNPs (scores > 500) and coverage ranging from 30 × 150x. We included 18, 12, and eight adult participants of ABPA, asthma, and healthy controls, respectively. The frequency of SNPs was higher in asthmatic subjects than ABPA or healthy controls, albeit not statistically significant (9/12 [75%] vs. 11/18 [61.1%] vs. 3/8 [37.5%], p = 0.24). Of the 38 subjects, 23 yielded 50 variants (healthy controls [n = 5], ABPA [n = 22], asthma [n = 23]) corresponding to six SNPs not previously linked with ABPA. Of these, four SNPs (rs213950, rs200735475, rs1800113, and rs1800136) were catalogued in the NCBI database. We identified two novel SNPs (chr7:117250703, chr7:117282655) in four (ABPA [n = 1], asthma [n = 3]) subjects without corresponding reference SNP. Most SNPs (85.5%) were heterozygous. The frequency of SNPs was higher in ABPA subjects with high-attenuation mucus (52.2%) and bronchiectasis (39.1%) than serological ABPA (8.7%). Our study suggests the role of CFTR mutations in the pathogenesis of ABPA. The SNPs in the CFTR gene may contribute to disease severity in ABPA. Larger studies are required to confirm our findings.
Sections du résumé
BACKGROUND
BACKGROUND
Whether cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations contribute to the high prevalence of allergic bronchopulmonary aspergillosis (ABPA) in India remains unknown. We aimed to evaluate the occurrence of CFTR mutations in subjects with ABPA complicating asthma.
METHODS
METHODS
We sequenced the CFTR gene using genomic DNA from blood on the Illumina NextSeq500 platform. Before undertaking zygosity analysis by genome analysis toolkit, the known or novel single nucleotide polymorphisms (SNPs) and indels were called. For rigorous analysis, we included only high-quality SNPs (scores > 500) and coverage ranging from 30 × 150x.
RESULTS
RESULTS
We included 18, 12, and eight adult participants of ABPA, asthma, and healthy controls, respectively. The frequency of SNPs was higher in asthmatic subjects than ABPA or healthy controls, albeit not statistically significant (9/12 [75%] vs. 11/18 [61.1%] vs. 3/8 [37.5%], p = 0.24). Of the 38 subjects, 23 yielded 50 variants (healthy controls [n = 5], ABPA [n = 22], asthma [n = 23]) corresponding to six SNPs not previously linked with ABPA. Of these, four SNPs (rs213950, rs200735475, rs1800113, and rs1800136) were catalogued in the NCBI database. We identified two novel SNPs (chr7:117250703, chr7:117282655) in four (ABPA [n = 1], asthma [n = 3]) subjects without corresponding reference SNP. Most SNPs (85.5%) were heterozygous. The frequency of SNPs was higher in ABPA subjects with high-attenuation mucus (52.2%) and bronchiectasis (39.1%) than serological ABPA (8.7%).
CONCLUSIONS
CONCLUSIONS
Our study suggests the role of CFTR mutations in the pathogenesis of ABPA. The SNPs in the CFTR gene may contribute to disease severity in ABPA. Larger studies are required to confirm our findings.
Identifiants
pubmed: 35430640
doi: 10.1007/s11046-022-00631-y
pii: 10.1007/s11046-022-00631-y
doi:
Substances chimiques
Cystic Fibrosis Transmembrane Conductance Regulator
126880-72-6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
147-155Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Agarwal R, Muthu V, Sehgal IS, Dhooria S, Prasad KT, Aggarwal AN. Allergic bronchopulmonary aspergillosis. Clin Chest Med. 2022;43(1):99–125.
doi: 10.1016/j.ccm.2021.12.002
Tracy MC, Okorie CUA, Foley EA, Moss RB. Allergic Bronchopulmonary Aspergillosis. J Fungi (Basel). 2016;2(2):17. https://doi.org/10.3390/jof2020017 .
doi: 10.3390/jof2020017
Kosmidis C, Denning DW. The clinical spectrum of pulmonary aspergillosis. Thorax. 2015;70(3):270–7. https://doi.org/10.1136/thoraxjnl-2014-206291 .
doi: 10.1136/thoraxjnl-2014-206291
pubmed: 25354514
Agarwal R, Devi D, Gupta D, Chakrabarti A. A questionnaire-based study on the role of environmental factors in allergic bronchopulmonary aspergillosis. Lung India. 2014;31(3):232–6. https://doi.org/10.4103/0970-2113.135762 .
doi: 10.4103/0970-2113.135762
pubmed: 25125809
pmcid: 4129594
Agarwal R, Khan A, Garg M, Aggarwal AN, Gupta D. Pictorial essay: Allergic bronchopulmonary aspergillosis. Ind J Radiol Imaging. 2011;21(4):242–52. https://doi.org/10.4103/0971-3026.90680 .
doi: 10.4103/0971-3026.90680
Moss RB, Hsu YP, Olds L. Cytokine dysregulation in activated cystic fibrosis (CF) peripheral lymphocytes. Clin Exp Immunol. 2000;120(3):518–25.
doi: 10.1046/j.1365-2249.2000.01232.x
Lara-Reyna S, Holbrook J, Jarosz-Griffiths HH, Peckham D, McDermott MF. Dysregulated signalling pathways in innate immune cells with cystic fibrosis mutations. Cell Mol Life Sci. 2020;77(22):4485–503. https://doi.org/10.1007/s00018-020-03540-9 .
doi: 10.1007/s00018-020-03540-9
pubmed: 32367193
pmcid: 7599191
Mueller C, Braag SA, Keeler A, Hodges C, Drumm M, Flotte TR. Lack of cystic fibrosis transmembrane conductance regulator in CD3+ lymphocytes leads to aberrant cytokine secretion and hyperinflammatory adaptive immune responses. Am J Respir Cell Mol Biol. 2011;44(6):922–9. https://doi.org/10.1165/rcmb.2010-0224OC .
doi: 10.1165/rcmb.2010-0224OC
pubmed: 20724552
Manti S, Parisi GF, Papale M, Marseglia GL, Licari A, Leonardi S. Type 2 inflammation in cystic fibrosis: new insights. Pediatr Allergy Immunol. 2022;33(Suppl 27):15–7. https://doi.org/10.1111/pai.13619 .
doi: 10.1111/pai.13619
pubmed: 35080292
Hartl D. Immunological mechanisms behind the cystic fibrosis-ABPA link. Med Mycol. 2009;47(Suppl 1):S183–91. https://doi.org/10.1080/13693780802189938 .
doi: 10.1080/13693780802189938
pubmed: 18651306
Allard JB, Poynter ME, Marr KA, Cohn L, Rincon M, Whittaker LA. Aspergillus fumigatus generates an enhanced Th2-biased immune response in mice with defective cystic fibrosis transmembrane conductance regulator. J Immunol. 2006;177(8):5186–94.
doi: 10.4049/jimmunol.177.8.5186
Maturu VN, Agarwal R. Prevalence of Aspergillus sensitization and allergic bronchopulmonary aspergillosis in cystic fibrosis: systematic review and meta-analysis. Clin Exp Allergy. 2015;45(12):1765–78. https://doi.org/10.1111/cea.12595 .
doi: 10.1111/cea.12595
pubmed: 26177981
Paranjape SM, Zeitlin PL. Atypical cystic fibrosis and CFTR-related diseases. Clin Rev Allergy Immunol. 2008;35(3):116–23. https://doi.org/10.1007/s12016-008-8083-0 .
doi: 10.1007/s12016-008-8083-0
pubmed: 18493878
Colbenson GA, Khawaja A, Baqir M, Wylam ME. A 48-Year-Old Woman With Chronic Cough, Dyspnea, and Bronchiectasis. Chest. 2020;158(5):e245–9. https://doi.org/10.1016/j.chest.2020.06.058 .
doi: 10.1016/j.chest.2020.06.058
pubmed: 33160546
Agarwal R. Burden and distinctive character of allergic bronchopulmonary aspergillosis in India. Mycopathologia. 2014;178(5–6):447–56. https://doi.org/10.1007/s11046-014-9767-z .
doi: 10.1007/s11046-014-9767-z
pubmed: 24947170
Agarwal R, Sehgal IS, Dhooria S, Muthu V, Prasad KT, Bal A, et al. Allergic bronchopulmonary aspergillosis. Ind J Med Res. 2020;151(6):529–49. https://doi.org/10.4103/ijmr.IJMR_1187_19 .
doi: 10.4103/ijmr.IJMR_1187_19
Denning DW, Pleuvry A, Cole DC. Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. Med Mycol. 2013;51(4):361–70. https://doi.org/10.3109/13693786.2012.738312 .
doi: 10.3109/13693786.2012.738312
pubmed: 23210682
Agarwal R, Denning DW, Chakrabarti A. Estimation of the burden of chronic and allergic pulmonary aspergillosis in India. PLoS ONE. 2014;9(12): e114745. https://doi.org/10.1371/journal.pone.0114745 .
doi: 10.1371/journal.pone.0114745
pubmed: 25478929
pmcid: 4257713
Shah A, Kala J, Sahay S, Panjabi C. Frequency of familial occurrence in 164 patients with allergic bronchopulmonary aspergillosis. Ann Allergy Asthma Immunol. 2008;101(4):363–9.
doi: 10.1016/S1081-1206(10)60311-0
Agarwal R, Khan A, Aggarwal AN, Gupta D. Link between CFTR mutations and ABPA: a systematic review and meta-analysis. Mycoses. 2012;55(4):357–65. https://doi.org/10.1111/j.1439-0507.2011.02130.x .
doi: 10.1111/j.1439-0507.2011.02130.x
pubmed: 21999194
Agarwal R, Chakrabarti A, Shah A, Gupta D, Meis JF, Guleria R, et al. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy. 2013;43(8):850–73. https://doi.org/10.1111/cea.12141 .
doi: 10.1111/cea.12141
pubmed: 23889240
Agarwal R, Dhooria S, Aggarwal AN, Maturu VN, Sehgal IS, Muthu V, et al. Guidelines for diagnosis and management of bronchial asthma: Joint ICS/NCCP (I) recommendations. Lung India. 2015;32(Suppl 1):S3–42. https://doi.org/10.4103/0970-2113.154517 .
doi: 10.4103/0970-2113.154517
pubmed: 25948889
pmcid: 4405919
Muthu V, Singh P, Choudhary H, Dhooria S, Sehgal IS, Prasad KT, et al. Role of recombinant Aspergillus fumigatus antigens in diagnosing Aspergillus sensitisation among asthmatics. Mycoses. 2020;63(9):928–36. https://doi.org/10.1111/myc.13124 .
doi: 10.1111/myc.13124
pubmed: 32490571
Sehgal IS, Dhooria S, Prasad KT, Muthu V, Aggarwal AN, Rawat A, et al. Sensitization to A fumigatus in subjects with non-cystic fibrosis bronchiectasis. Mycoses. 2021;64(4):412–9. https://doi.org/10.1111/myc.13229 .
doi: 10.1111/myc.13229
pubmed: 33332671
Muthu V, Sehgal IS, Prasad KT, Dhooria S, Garg M, Aggarwal AN, et al. Epidemiology and outcomes of allergic bronchopulmonary aspergillosis in the elderly. Mycoses. 2022;65(1):71–8. https://doi.org/10.1111/myc.13388 .
doi: 10.1111/myc.13388
pubmed: 34724277
Marchand E, Verellen-Dumoulin C, Mairesse M, Delaunois L, Brancaleone P, Rahier JF, et al. Frequency of cystic fibrosis transmembrane conductance regulator gene mutations and 5T allele in patients with allergic bronchopulmonary aspergillosis. Chest. 2001;119(3):762–7.
doi: 10.1378/chest.119.3.762
Eaton TE, Weiner Miller P, Garrett JE, Cutting GR. Cystic fibrosis transmembrane conductance regulator gene mutations: do they play a role in the aetiology of allergic bronchopulmonary aspergillosis? Clin Exp Allergy. 2002;32(5):756–61. https://doi.org/10.1046/j.1365-2222.2002.01361.x .
doi: 10.1046/j.1365-2222.2002.01361.x
pubmed: 11994102
Gamaletsou MN, Hayes G, Harris C, Brock J, Muldoon EG, Denning DW. F508del CFTR gene mutation in patients with allergic bronchopulmonary aspergillosis. J Asthma. 2018;55(8):837–43. https://doi.org/10.1080/02770903.2017.1373808 .
doi: 10.1080/02770903.2017.1373808
pubmed: 29035608
Miller PW, Hamosh A, Macek M Jr, Greenberger PA, MacLean J, Walden SM, et al. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in allergic bronchopulmonary aspergillosis. Am J Hum Genet. 1996;59(1):45–51.
pubmed: 8659542
pmcid: 1915108
Aron Y, Bienvenu T, Hubert D, Dusser D, Dall’Ava J, Polla BS. HLA-DR polymorphism in allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol. 1999;104(4 Pt 1):891–2. https://doi.org/10.1016/s0091-6749(99)70306-4 .
doi: 10.1016/s0091-6749(99)70306-4
pubmed: 10518840
Lebecque P, Pepermans X, Marchand E, Leonard A, Leal T. ABPA in adulthood: a CFTR-related disorder. Thorax. 2011;66(6):540–1. https://doi.org/10.1136/thx.2010.145862 .
doi: 10.1136/thx.2010.145862
pubmed: 20837875
Kapoor V, Shastri SS, Kabra M, Kabra SK, Ramachandran V, Arora S, et al. Carrier frequency of F508del mutation of cystic fibrosis in Indian population. J Cyst Fibros. 2006;5(1):43–6. https://doi.org/10.1016/j.jcf.2005.10.002 .
doi: 10.1016/j.jcf.2005.10.002
pubmed: 16311077
Shastri SS, Kabra M, Kabra SK, Pandey RM, Menon PS. Characterisation of mutations and genotype-phenotype correlation in cystic fibrosis: experience from India. J Cyst Fibros. 2008;7(2):110–5. https://doi.org/10.1016/j.jcf.2007.06.004 .
doi: 10.1016/j.jcf.2007.06.004
pubmed: 17716958
Alibakhshi R, Mohammadi A, Khamooshian S, Kazeminia M, Moradi K. CFTR gene mutation spectrum among 735 Iranian patients with cystic fibrosis: A comprehensive systematic review. Pediatr Pulmonol. 2021;56(12):3644–56. https://doi.org/10.1002/ppul.25647 .
doi: 10.1002/ppul.25647
pubmed: 34525262
Crespo-Lessmann A, Bernal S, Del Río E, Rojas E, Martínez-Rivera C, Marina N, et al. Association of the CFTR gene with asthma and airway mucus hypersecretion. PLoS ONE. 2021;16(6): e0251881. https://doi.org/10.1371/journal.pone.0251881 .
doi: 10.1371/journal.pone.0251881
pubmed: 34086689
pmcid: 8177500
Schroeder SA, Gaughan DM, Swift M. Protection against bronchial asthma by CFTR delta F508 mutation: a heterozygote advantage in cystic fibrosis. Nat Med. 1995;1(7):703–5.
doi: 10.1038/nm0795-703
Kim KW, Lee JH, Lee MG, Kim KH, Sohn MH, Kim KE. Association between cystic fibrosis transmembrane conductance regulator gene mutations and susceptibility for childhood asthma in Korea. Yonsei Med J. 2010;51(6):912–7. https://doi.org/10.3349/ymj.2010.51.6.912 .
doi: 10.3349/ymj.2010.51.6.912
pubmed: 20879059
pmcid: 2995957
Agarwal R. Severe asthma with fungal sensitization. Curr Allergy Asthma Rep. 2011;11(5):403–13. https://doi.org/10.1007/s11882-011-0217-4 .
doi: 10.1007/s11882-011-0217-4
pubmed: 21789577
Garred P, Pressler T, Madsen HO, Frederiksen B, Svejgaard A, Hoiby N, et al. Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J Clin Invest. 1999;104(4):431–7. https://doi.org/10.1172/JCI6861 .
doi: 10.1172/JCI6861
pubmed: 10449435
pmcid: 408526
Drumm ML, Konstan MW, Schluchter MD, Handler A, Pace R, Zou F, et al. Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med. 2005;353(14):1443–53. https://doi.org/10.1056/NEJMoa051469 .
doi: 10.1056/NEJMoa051469
pubmed: 16207846
Dorfman R, Sandford A, Taylor C, Huang B, Frangolias D, Wang Y, et al. Complex two-gene modulation of lung disease severity in children with cystic fibrosis. J Clin Invest. 2008;118(3):1040–9. https://doi.org/10.1172/JCI33754 .
doi: 10.1172/JCI33754
pubmed: 18292811
pmcid: 2248329
Shanthikumar S, Neeland MN, Saffery R, Ranganathan S. Gene modifiers of cystic fibrosis lung disease: A systematic review. Pediatr Pulmonol. 2019;54(9):1356–66. https://doi.org/10.1002/ppul.24366 .
doi: 10.1002/ppul.24366
pubmed: 31140758
Manti S, Parisi GF, Papale M, Licari A, Chiappini E, Mulè E, et al. Allergic bronchopulmonary aspergillosis in children. Pediatr Allergy Immunol. 2020;31(Suppl 26):20–2. https://doi.org/10.1111/pai.13357 .
doi: 10.1111/pai.13357
pubmed: 33236425